文献速递乳腺PET

双探测器系统分子乳腺成像引导活检

Molecular Breast Imaging Biopsy with a Dual-Detector System.
PubMed 文献 · Radiol Imaging Cancer · 2024-01-01

研究开发了双探测器分子乳腺成像引导活检系统,并在前瞻性研究中评估其可行性。21名参与者中17人完成活检且病理一致,平均病灶大小17 mm,平均操作时间55分钟。结论认为该系统可行、耐受良好且高效。

要点

  • 双探测器MBI引导活检系统通过上探测器0°和15°三角测量计算病灶深度。
  • 17/21例完成活检,4例活检时未见病灶,平均操作时间55分钟。
  • 病理结果包括浸润性导管癌1例、纤维腺瘤4例、假血管瘤样间质增生6例、纤维囊性变6例。

核心结论

  • 使用上探测器可回缩的双头系统进行MBI引导活检是可行的、耐受良好且高效的。

研究设计与样本

  • 前瞻性研究(2022年7月至2023年6月),纳入21名具有BI-RADS 2、3、4或5类乳腺病灶的参与者,使用Stereo Navigator MBI附件活检系统,注射740 MBq锝99m司他比后进行MBI引导活检,以病理为参考标准。

诊断标准与关键数值

  • 通过上探测器在0°和15°的病灶位置三角测量及上下探测器相对病灶活性计算病灶深度;注射740 MBq锝99m司他比后行头尾位和内外斜位MBI(每视野2分钟采集)确认病灶显影。

临床应用与阅片要点

  • 上探测器回缩后可放置活检装置,标本影像在上探测器上获取以确认取样目标。

局限性

  • 4名参与者在活检时未观察到病灶。
  • 平均病灶大小17 mm(范围6-38 mm),平均操作时间55分钟±13(范围38-90分钟)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To develop a molecular breast imaging (MBI)-guided biopsy system using dual-detector MBI and to perform initial testing in participants. Materials and Methods The Stereo Navigator MBI Accessory biopsy system comprises a lower detector, upper fenestrated compression paddle, and upper detector. The upper detector retracts, allowing craniocaudal, oblique, or medial or lateral biopsy approaches. The compression paddle allows insertion of a needle guide and needle. Lesion depth is calculated by triangulation of lesion location on the upper detector at 0° and 15° and relative lesion activity on upper and lower detectors. In a prospective study (July 2022-June 2023), participants with Breast Imaging Reporting and Data System category 2, 3, 4, or 5 breast lesions underwent MBI-guided biopsy. After injection of 740 MBq technetium 99m sestamibi, craniocaudal and mediolateral oblique MBI (2-minute acquisition per view) confirmed lesion visualization. A region of interest over the lesion permitted depth calculation in the system software. Upper detector retraction allowed biopsy device placement. Specimen images were obtained on the retracted upper detector, confirming sampling of the target. Results Of 21 participants enrolled (mean age, 50.6 years ± 10.1 [SD]; 21 [100%] women), 17 underwent MBI-guided biopsy with concordant pathology. No lesion was observed at the time of biopsy in four participants. Average lesion size was 17 mm (range, 6-38 mm). Average procedure time, including preprocedure imaging, was 55 minutes ± 13 (range, 38-90 minutes). Pathology results included invasive ductal carcinoma (n = 1), fibroadenoma (n = 4), pseudoangiomatous stromal hyperplasia (n = 6), and fibrocystic changes (n = 6). Conclusion MBI-guided biopsy using a dual-head system with retractable upper detector head was feasible, well tolerated, and efficient. Keywords: Breast Biopsy, Molecular Breast Imaging, Image-guided Biopsy, Molecular Breast Imaging-guided Biopsy, Breast Cancer Clinical trial registration no. NCT06058650 © RSNA, 2024.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Hunt KN, Conners AL, Gray L, et al. Molecular Breast Imaging Biopsy with a Dual-Detector System. Radiol Imaging Cancer. 2024. PMID: 38847615. doi:10.1148/rycan.230186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。